

REMARKS


Claims 1, 4-10, 14-16, 18-20, 23-33, 35-46 and 51-54 are currently pending. Claims 1, 14, 15, 18-20, 23-26, and 33 have been amended herein, claims 2, 3, 11, 12, 17, 21, 22, and 34 have been cancelled herein, and claims 51-54 have been newly introduced herein. Claims 1 and 33 have been rewritten to incorporate limitations of claim 3, previously indicated as allowable if rewritten to include the limitations of base claims 1 and 34, respectively. Claims 14, 15, 18-20, and 23-26 have been amended to change their dependencies to claims which have previously been indicated as allowable, thus rendering them also allowable. Additionally, the independent claims (1, 33, and 51-54) have been amended in their format by indentation.

Claim 51 is a new claim, which is claim 1 including the limitations of claim 12, previously indicated as allowable if rewritten to include the limitations of the base claim. Claim 52 is a new claim, which is claim 1 including the limitations of claim 17, previously indicated as allowable if rewritten to include the limitations of the base claim. Claim 53 is a new claim, which is claim 1 including the limitations of claim 21, previously indicated as allowable if rewritten to include the limitations of the base claim. Claim 54 is a new claim, which is claim 1 including the limitations of claim 22, previously indicated as allowable if rewritten to include the limitations of the base claim. No new matter is introduced by these amendments or new claims.

All pending claims are now believed allowable, and the Examiner is respectfully requested to issue a Notice of Allowance at the earliest opportunity.

Respectfully submitted,

TALWAR et al.

By:   
George E. Heibel, PhD.  
Reg. No. 42,648

Date: September 20, 2004

Correspondence Address:  
Ranbaxy Inc.  
600 College Road East, Suite 2100  
Princeton, NJ 08540  
Telephone: (609) 720-5334  
Facsimile: (609) 514-9779